Targeted Sequencing And Resequencing Market
Report ID: SQMIG35J2273
Report ID: SQMIG35J2273
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2273 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
119
|Figures:
72
Global Targeted Sequencing And Resequencing Market size was valued at USD 5.52 Billion in 2024 and is poised to grow from USD 6.16 Billion in 2025 to USD 14.85 Billion by 2033, growing at a CAGR of 11.52% during the forecast period (2026-2033).
The targeted sequencing and resequencing market growth is being driven, primarily, by the need for cost effective approaches with high throughput (quick turnaround) in the use of genetics as part of Precision Medicine. The purpose of targeted sequencing is to utilize defined genomic regions to generate greater sensitivity and lesser data burden than that produced when performing an overall sequencing, while the goal of resequencing is to identify variations against a reference genome when comparing samples. These fields are important because both clinicians and researchers require faster, cheaper and more actionable genomic data than that provided by traditional whole-genome approaches in order to effectively utilize genetics as a component of Precision Medicine.
As new methods for next-generation sequencing (NGS) are developed (including advances in sequencing chemistry, library preparation, and bioinformatics), costs for NGS have dramatically decreased, resulting in an increase in the use of these technologies. Clinical examples of this innovation include oncology panels for actionable mutations and large population-based genomic studies. The improved accessibility to NGS has stimulated the continued growth of this fields through the integration of targeted assays into clinical workflow systems. With validated panels and companion diagnostic devices existing, there is clear clinical utility associated with these products. As a result, they are able to obtain the reimbursement that is required for payors, providers, and health systems to implement these tests in their practice.
The need for accelerated and actionable mutation calls has increased the demand for targeted panels, resulting in manufacturers of such products expanding their offerings of assays and analytics. The existence of real-world case examples such as liquid biopsy monitoring for cancer patients, rapid pathogen resequencing during an outbreak, and testing newborns to establish a baseline of use, have attracted even further investment into this field of analysis.
How is AI Enhancing Data Analysis In The Targeted Sequencing And Resequencing Market?
Targeted sequencing and resequencing concentrate on specific genomic regions to provide thorough and clinically significant coverage. Artificial Intelligence is enhancing key steps throughout the process. For example, machine learning provides refined base calling and error correction, and subsequently prioritizes the order of the variant calls for interpretation while also providing functional impact predictions. Furthermore, AI provides imputation from limited panels and integrates multi modal signals for easier reporting. The market is transitioning from use for exploratory research to a highly utilized tool for routine clinical use in both oncology and infectious disease, thus creating an increased demand for more rapid and interpretable results. Example of AI-enhanced technologies include MRD detection in oncology and pathogen profiling to decrease diagnosis timelines in cancers.
In March 2026, Lucence announced an enhanced UNITED test using whole exome and transcriptome sequencing and AI technology to streamline the analysis and reporting process. Through innovations like these, AI is creating a process that reduces analytical bottlenecks, makes complex targeted and re-sequencing results into concise clinical insights, and gives laboratories the means to implement more comprehensive assays thereby supporting broader acceptance in the marketplace and expediting patient care.
Market snapshot - (2026-2033)
Global Market Size
USD 5.52 Billion
Largest Segment
Amplicon-Based Sequencing
Fastest Growth
RNA Sequencing
Growth Rate
11.52% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global targeted sequencing and resequencing market is segmented by sequencing method, product, application, end-user and region. Based on sequencing method, the market is segmented into Amplicon-Based Sequencing, Hybridization Capture, Whole Exome Sequencing and RNA Sequencing. Based on product, the market is segmented into Instruments, Reagents & Kits and Software. Based on application, the market is segmented into Oncology, Inherited Diseases, Infectious Disease and Pharmacogenomics. Based on end-user, the market is segmented into Pharma & Biotech, Clinical Labs and Academic Research. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per global targeted sequencing and resequencing market analysis, due to the use of PCR-based workflows and their smaller footprint, the Amplicon-Based Sequencing category has a dominant position because it focuses sequencing efforts on regions of interest, allowing for a lower cost per sample and simplified library preparation. The concentrated nature of the approach leads to greater on-target rates and faster turnaround times, leading to its use in routine clinical and high-throughput research settings. As assay development becomes easier and validation pathways are clearer, there will be increased demand for standardized amplicon solutions to provide a stable preference in the market so that clinical decisions can be made more quickly.
As per global targeted sequencing and resequencing market forecast, the Hybridization Capture category is growing fastest because improvements in probe design allow for broader and more uniform coverage over larger regions of the genome, extending the utility of hybridization capture for complex panels and exome scale targets. Improvements in automation and probe chemistry have reduced hands-on time, drawing interest from both translational research and clinical studies, as well as creating new opportunities for applications in other areas of disease.
As per global targeted sequencing and resequencing market outlook, the Reagents and Kits sector leads the field because standardised and validated consumables are crucial for enabling reliable, targeted sequencing workflows and supporting vendor investment through recurrent revenue streams. Using ready-to-use library prep kits and targeted panel reagents ensures quicker assay development and regulatory paths to clinical adoption and trial deployment. As laboratories continue to emphasis on reproducibility and increased throughput, the availability of optimised reagents will reduce technical variability and lead to a greater level of integration of targeted sequencing across diagnostic and research workflows.
In contrast, software continues to be the fastest growing area with improvements made in bioinformatics, variant interpretation and cloud-based analysis that have removed bottlenecks in data processing and reporting. By enhancing user interfaces, offering regulatory ready pipelines, and providing AI-assisted annotation, new models for clinical decision making and trial readouts will open up new service offerings to allow smaller laboratories to incorporate complex targeted assays and grow their testing portfolios.
To get detailed segments analysis, Request a Free Sample Report
As per global targeted sequencing and resequencing market regional analysis, because of a combination of innovation, infrastructure, and market maturity, North America is leading in quickly moving sequencing technologies into clinical and research settings. The dense ecosystem of established instrument and reagent makers, along with specialized service providers and reference laboratories, supports the rapid development of new products and their broad availability in the marketplace. Strong collaboration among academic medical centers, pharmaceutical companies, and diagnostic laboratories helps to bring targeted panels and resequencing workflows into widespread use. In addition, there is clear guidance from regulators, as well as a pre-existing dialogue on reimbursement for test results by payers (e.g., insurance companies), which creates a more predictable environment in which new tests can be sold commercially. Demand for targeted approaches to oncology, rare diseases, and companion diagnostics will be fuelled by robust translational research programs and collaborative networks, while a well-trained workforce and logistics infrastructure will provide the necessary support to allow for operational scalability throughout the whole area.
In North America, the Targeted Sequencing and Resequencing Market is characterized by strong clinical integration and strong leadership in private sector organizations. Major instrument and consumable companies, large amounts of investment in related ventures and industries, and extensive clinical trial activity drive adoption of targeted workflows in oncology, hereditary diseases, and translational research. Academic medical centers and commercial reference laboratories serve as early adopters and validation partners, thereby facilitating the commercialization of new panels and bioinformatics solutions. Clinic-wide diagnostic pathways that have already been established; engagement by payers with their respective payer mixes; and a large number of service providers create a framework that makes it possible for this technology to be used more broadly across the healthcare continuum as well as provide additional availability through scalability and the number of service providers.
The Targeted Sequencing and Resequencing Market in Canada benefits from a coordinated public healthcare system and collaborative research networks that enable the implementation of targeted assays for clinical use. Provincial laboratory systems and national research consortia exist to facilitate centralized adoption of targeted assays for oncology and rare disease diagnostics. Academic institutions and federally funded research centres are developing and validating methodology. In order to have access to the latest technology, international vendors, reference laboratories, and academic institutions are developing partnerships with each other. The focus of the Targeted Sequencing and Resequencing Market is to ensure that there is equitable access and clinical utility of the application as well as that the application integrates with public health initiatives and provides for steady growth in the number of targeted sequencing applications over time.
As per global targeted sequencing and resequencing market regional forecast, strategic public initiatives, strong partnerships between academia and industry, and increasing attention to precision medicine in national health systems, contribute to the current rapid growth of Europe. Investment in national genomic programs and cross-border research consortia has led to demand for local targeted sequencing solutions to meet clinical needs. Having varying levels of expertise among imaging and diagnostic manufacturers, as well as specialized service laboratories, and bioinformatics providers provides for the customization and commercialization of these solutions in the local or regional markets. Changing regulatory environments and health technology assessment processes govern how targeted sequencing technologies will be introduced into the marketplace. There is strong collaborative effort between hospitals and industry to support the clinical adoption of targeted sequencing in oncology and rare disease applications. Different dynamics at the country-level provide pockets of advanced capabilities and emerging markets, thereby enhancing the overall strength of Europe in targeted sequencing technologies.
The German Targeted Sequencing And Resequencing Market is characterized by the deep integration of a well-established diagnostics industry with advanced clinical laboratory networks. Hospitals, molecular pathology units in hospitals, specialized biotechnology companies, and contract research organizations all play a significant role in driving the adoption of targeted panels for oncology and hereditary conditions. Quality assurance standards and robust reimbursement discussions support clinical use, while local manufacturing capabilities and supplier ecosystems ensure the availability of targeted panels. Collaborative partnerships between research institutions and industry support the validation and adoption of new assays, establishing the German Targeted Sequencing And Resequencing Market as a key hub in the region for precision diagnostics.
The UK Targeted Sequencing And Resequencing Market is driven by national genomic initiatives and integrated clinical genomic healthcare infrastructures that accelerate the translation into routine care. Partnerships among health service providers, academic institutions, and industry allow for the rapid piloting and scaling of targeted diagnostic tests, particularly for cancers and inherited diseases. A strong startup community and strong clinical leadership create iterative improvements in targeted panels and informatics solutions. Focus on streamlined pathways for generating evidence and achieving system-wide adoption has created momentum within the UK Targeted Sequencing And Resequencing Market in both public and private healthcare settings.
In the French market for targeted sequencing and resequencing, there is evidence of collaboration and strategic public investment in genomic medicine from both laboratory- and national-level organisations. As a result, hospitals, national research organisations and new service providers are working together to provide comprehensive targeted assays for cancer profiling and genetic diagnostics. Further development of this market is supported by an emphasis on clinical validation, data integration and regional collaboration among key stakeholders. Additionally, continued development of strategic partnerships across the industry and initiatives aimed at standardising the testing pathway will ultimately create an environment that is helping to move the industry forward: from a variety of pilot programmes to a growing number of broader, clinically applicable programmes.
Targeted investments in domestic medium-sized manufacturing, extending sequencing (information technology) and implementing strategic public policy, specifically related to precision medicine and biotechnology innovation, continue to provide strong evidence that Asia Pacific is solidifying its position as a leader. Component and product development opportunities from regional markets based on existing employee talent, regional labor cost advantages and developing specialized panels; bioinformatics pipelines; and service models for various clinical conditions are providing distinctive value-enhancing factors. The joint development of cross-border relationships and partnerships with global technology companies improves the ability of organizations and their staff to access and employ knowledge/skills. This has resulted in a marked increase in the number of international clinical trials being conducted; additionally, the growing demand for cancer care from Asia Pacific population genomics initiatives has greatly increased credibility and adoption of this region. Collectively, these developments are facilitating Asia Pacific's movement from the implementation stage to becoming a recognized leader in selected areas of focused sequencing/re-sequencing.
In Japan, the high-quality diagnostic service industry is supported by a mature life sciences sector and a well-established clinical laboratory infrastructure. Local instrument and reagent manufacturers work closely with hospitals and research institutions to develop targeted panels that meet the local clinical needs of oncology and other diseases. The regulatory framework in Japan promotes the clinical validation and integration of genomic tests into the clinical care delivery model, while the strong linkages between industry and academia foster translational research and commercialization. In addition to precision, quality and alignment with clinical workflows, the targeted sequencing and resequencing market will also drive down the cost of clinical care.
The rapid adoption of technology and the concentration of research and development expertise, combined with the supportive government policies for biotechnology initiatives, are the driving forces behind the growth of the targeted sequencing and resequencing market in South Korea. In addition, a network of advanced clinical laboratories and technology companies will develop localized targeted solutions and streamline bioinformatics services. South Korea's strong global export orientation and strong collaboration with global partners will foster large-scale innovation and will enable the rapid adoption of new targeted assays and services within the clinical care delivery model. As a result of the rapid increase in clinical trial activity and hospital engagement within the oncology and rare disease diagnostic sectors, the South Korean targeted sequencing and resequencing market will be characterized by nimble commercialization and the integration of new targeted assays into the clinical care delivery model.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advances In Sequencing Technologies
Growing Clinical and Research Applications
High Upfront Instrument Costs
The lack of financial resources for advanced sequencing instruments and their associated infrastructures may inhibit the adoption of these instruments by smaller clinical laboratories and research facilities. If budgetary constraints prioritize existing operations, decision-makers may forgo or delay purchasing targeted sequencing platforms, thereby decreasing the number of potential customers for manufacturers. Therefore, such a situation may cause demand (i.e., customers) to shift towards centralized testing centers/service providers and create a less fragmented market for targeted sequencing and reduce the speed at which in-house testing capabilities are adopted by customers (the targeted sequencing and resequencing market will, therefore, grow at a slower pace).
Complex Data Interpretation Challenges
Request Free Customization of this report to help us to meet your business objectives.
The level of competition within the global targeted sequencing and resequencing market is increasing as established competitors employ both acquisition and merger strategies as well as increasing integration of their wills to defend share position. Examples of this are Illumina's recent acquisition of Fluent in order to increase the capabilities of single cell preparation and library preparation and Twist Bioscience's collaborative agreement with Element Biosciences to develop libraries together for use in Trinity target enrichment methods that will be used in future studies. All these developments are being driven from customer demand for more integrated library /target enrichment to reduce time from the preparation of the sample to receipt of the final report.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global targeted sequencing and resequencing market is driven primarily by demand for cost-effective, high-throughput genetic interrogation that supports precision medicine, and further propelled by integration of targeted assays into clinical workflows which enhances reimbursement and adoption. Growth is restrained by high upfront instrument costs that favor centralized testing over decentralized labs and slow in-house uptake. North America remains the dominating region thanks to mature infrastructure and strong clinical–industry linkages. While amplicon-based sequencing is the dominating segment because its PCR-driven, compact panels lower per-sample cost and speed turnaround. Overall, these forces point to sustained adoption and expanded clinical utility.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 5.52 Billion |
| Market size value in 2033 | USD 14.85 Billion |
| Growth Rate | 11.52% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Targeted Sequencing And Resequencing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Targeted Sequencing And Resequencing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Targeted Sequencing And Resequencing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Targeted Sequencing And Resequencing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Targeted Sequencing And Resequencing Market size was valued at USD 5.52 Billion in 2024 and is poised to grow from USD 6.16 Billion in 2025 to USD 14.85 Billion by 2033, growing at a CAGR of 11.52% during the forecast period (2026-2033).
Competitive pressure in the global targeted sequencing and resequencing market is intensifying as incumbent firms use acquisitions, partnerships, and workflow integration to defend share. Recent examples include Illumina’s acquisition of Fluent to broaden single cell and library prep capabilities and Twist Bioscience’s expanded collaboration with Element Biosciences to co develop Trinity target enrichment workflows, driven by customer demand for integrated library prep and target enrichment to shorten time to result. 'Illumina Inc.', 'Thermo Fisher Scientific', 'Qiagen NV', 'Agilent Technologies', 'Roche', 'Pacific Biosciences', 'Oxford Nanopore Technologies', 'BGI Genomics', 'Twist Bioscience', 'Integrated DNA Technologies (IDT)', 'Genoptix (Novartis)', 'Foundation Medicine (Roche)', 'Guardant Health', 'Tempus Labs', 'Grail Inc.'
Recent technological improvements in sequencing platforms have enhanced accuracy, speed, and flexibility, enabling laboratories to target specific genomic regions more efficiently. These advances reduce the technical barriers to implementing targeted panels and allow providers to tailor assays to clinical and research needs, which broadens the range of applications for targeted sequencing and resequencing. By improving workflow integration and compatibility with downstream analysis, novel instruments and chemistries stimulate greater adoption among diagnostic labs, biopharma, and academic centers, thereby driving market expansion.
Integration With Clinical Diagnostics: The convergence of targeted sequencing with routine clinical diagnostics is accelerating adoption across care settings. Laboratories are integrating targeted panels into diagnostic workflows to support therapy selection, disease monitoring, and early detection strategies. This shift emphasizes standardized sample processing, streamlined reporting, and closer collaboration between laboratory scientists and clinicians. As clinical utility narratives strengthen, payers and providers increasingly recognize the value of targeted assays for personalized care, driving investments in validation, quality management, and clinician education to ensure reliable implementation.
Why does North America Dominate the Global Targeted Sequencing And Resequencing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
